Apotex: Amgen Attempting To Obtain 'Undeserved' Profits
This article was originally published in Scrip
Executive Summary
A preliminary injunction (PI) Amgen Inc. won this past December from a district court blocking Toronto-based Apotex Inc. from marketing its biosimilar version of the California biotech giant's long-acting human granulocyte colony-stimulating factor Neulasta (pegfilgrastim) for 180 days after the FDA licenses it is an "undisguised ploy to get an extra six months of undeserved monopoly profits based on a crabbed reading" of the Biologics Price Competition and Innovation Act (BPCIA), the latter company asserted in new court documents.